Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 19/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19173949 | 0.85 | HSD11B1 (0.74) | HSD11B1SMN1; SMN2 | |
| SCHEMBL19173475 | 0.76 | HSD11B1 (1.00) | HSD11B1SMN1; SMN2 | |
| SCHEMBL12577159 | 0.65 | HSD11B1 (0.80) | HSD11B1SMN1; SMN2 | |
| SCHEMBL19172961 | 0.63 | HSD11B1 (1.00) | HSD11B1SMN1; SMN2 | |
| SCHEMBL10211716 | 0.63 | ALDH1A1 (0.69) | SMN1; SMN2 | |
| SCHEMBL22171222 | 0.62 | SLC18A3 (0.70) | — | |
| SCHEMBL19173935 | 0.62 | HSD11B1 (1.00) | HSD11B1SMN1; SMN2 | |
| SCHEMBL19173686 | 0.60 | KMT2A (0.60) | HSD11B1SMN1; SMN2 | |
| SCHEMBL14538284 | 0.60 | HTR2A (0.52) | — | |
| SCHEMBL5513049 | 0.59 | HTR2A (0.51) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238265-A1 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | IFNAR1, NR4A3, NR0B2 | HSD11B1 2165/4885SMN1; SMN2 1174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.